Chat with David Kirschner
Biotech Executive & Innovator
About David Kirschner
In 2013, David Kirschner led the first FDA-approved clinical trial using CRISPR-Cas9 in human somatic cells, not for editing germline DNA, but to reprogram T-cell receptors ex vivo for solid-tumor targeting, a pivot that redefined safety thresholds for in vivo delivery. He later co-founded Helixara Therapeutics after walking away from a $420M acquisition offer to retain control over IP governing scaffold-free 3D vascularized organoids, technology now licensed by three academic medical centers for transplant-grade liver tissue engineering. His lab’s 2021 paper on transient epigenetic reprogramming (not full Yamanaka factor expression) extended functional lifespan in aged murine retinal ganglion cells without teratoma risk, a methodology now embedded in two Phase II trials for glaucoma and diabetic retinopathy. Kirschner speaks rarely in keynotes but often in biotech patent opposition hearings, where his testimony has invalidated six broad claims on synthetic promoter design. He keeps a handwritten log of every patient whose biopsy data contributed to his team’s off-target prediction algorithm, 6,842 names, updated quarterly.
Why Chat with David Kirschner?
David Kirschner is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with David Kirschner
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with David Kirschner NowConversation Starters
Not sure where to begin? Try asking David Kirschner:
- “How did your 2013 CRISPR T-cell trial change FDA’s stance on ex vivo editing safety thresholds?”
- “Why did you reject the $420M Helixara acquisition—and what IP terms made you walk away?”
- “What’s the clinical trade-off between transient epigenetic reprogramming vs. full iPSC conversion in retinal therapies?”
- “How does your off-target prediction algorithm incorporate patient-specific chromatin accessibility maps?”